

LIFE SCIENCES SEMINARS



"USING MOLECULAR IMAGING OF BRAIN AMYLOID AND TAU IN ALZHEIMER'S DISEASE CLINICAL TREATMENT TRIALS: THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI)"

MICHAEL WEINER, M.D.
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

Alzheimer's disease (AD) is an "amyloid-facilitated tauopathy" associated with synaptic dysfunction and neuronal loss, causing progressive memory impairments and cognitive dysfunction, leading to dementia and death. Currently there is no treatment that slows the progression of AD. However, a recent small trial by Biogen using a human antibody has shown dramatic effects to lower brain amyloid load, and suggested a beneficial clinical effect. Until recently, AD was diagnosed with clinical measures, or by autopsy. However, in the past decade a number of biomarkers, including MRI, PET, and cerebrospinal fluid (CSF) markers, have been used to characterize the pathology with reasonable sensitivity and specificity. The goal of ADNI (see ADNI-info.org) has been to standardize and validate MRI and PET imaging and blood/CSF biomarkers for Alzheimer's treatment.

TUES., SEPT. 29TH
4:00 P.M.

717 POTTER STREET
ROOM 141
BERKELEY LAB

HOST:
WILLIAM JAGUST

Schedule of Seminars: lsd.lbl.gov/News_&_Events/seminars.html
Non-LBNL attendees: please RSVP to MRoach@lbl.gov or 510-486-6050